Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 12/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 10/20 | 1.00 |
| ▸ | THRA | P10827 | 6/20 | 1.00 |
| ▸ | THRB | P10828 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905318 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16225997 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16226604 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL8984288 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL8984283 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16226603 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16226350 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16226164 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL16226351 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL6905321 | 1.00 | ATG4B (1.00) | ATG4BPLA2G1BTHRATHRBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2013177492-A2 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ATG4B 4484/4885PLA2G1B 2591/4885THRA 26/4885 |
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | ATG4B 641/4885PLA2G1B 64/4885THRA 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.